SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 73 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $78,000 | -19.6% | 10,419 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $97,000 | +76.4% | 10,419 | 0.0% | 0.00% | +50.0% |
| Q1 2019 | $55,000 | -1.8% | 10,419 | -17.7% | 0.00% | -33.3% |
| Q4 2018 | $56,000 | -94.0% | 12,663 | -90.4% | 0.00% | -93.6% |
| Q2 2018 | $929,000 | -50.7% | 132,318 | 0.0% | 0.05% | -64.1% |
| Q1 2018 | $1,883,000 | +62.5% | 132,318 | 0.0% | 0.13% | +79.5% |
| Q4 2017 | $1,159,000 | -32.7% | 132,318 | -10.0% | 0.07% | -24.7% |
| Q3 2017 | $1,721,000 | -10.6% | 147,072 | +6.8% | 0.10% | -6.7% |
| Q2 2017 | $1,924,000 | +68.6% | 137,732 | +65.6% | 0.10% | +79.3% |
| Q1 2017 | $1,141,000 | +91.4% | 83,172 | 0.0% | 0.06% | +65.7% |
| Q4 2016 | $596,000 | -68.1% | 83,172 | -32.5% | 0.04% | -76.7% |
| Q3 2016 | $1,867,000 | +145.7% | 123,136 | +1329.8% | 0.15% | +368.8% |
| Q2 2016 | $760,000 | -80.2% | 8,612 | -97.0% | 0.03% | -75.6% |
| Q1 2016 | $3,846,000 | – | 288,750 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 956,165 | $20,930,000 | 11.19% |
| Aisling Capital Management LP | 1,025,000 | $22,437,000 | 7.92% |
| FRAZIER MANAGEMENT LLC | 2,772,062 | $60,680,000 | 4.67% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,176,585 | $25,755,000 | 2.83% |
| Paradigm Biocapital Advisors LP | 453,091 | $9,918,000 | 2.83% |
| Ghost Tree Capital, LLC | 300,000 | $6,567,000 | 2.35% |
| Avidity Partners Management LP | 4,823,400 | $105,584,000 | 2.24% |
| Nantahala Capital Management | 2,850,559 | $62,399,000 | 2.20% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $4,512,000 | 1.90% |
| BVF INC/IL | 2,099,714 | $45,963,000 | 1.67% |